November 26, 2026

To, **National Stock Exchange of India Limited**, "Exchange Plaza", 5th Floor, Plot No. C/1, G Block, Bandra- Kurla Complex, Bandra (East), Mumbai – 400 051	To, **BSE Limited**, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001
Scrip Name: GLENMARK	**Scrip Code: 532296**
ISIN: INE935A01035	**ISIN: INE935A01035**
Our Reference No. 73/26-27	**Our Reference No. 73/26-27**

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR") - Schedule of Analyst/ Institutional Investor Meetings

With reference to the captioned subject and pursuant to the Regulation 30 and Para A of Part A of Schedule III of the SEBI LODR, we would like to inform details of the Analyst/ Institutional Investor meeting to be conducted as follows:

Date	Analyst/Institutional Investors/Event	Venue	Type of Meeting	Group / One-on-one
1 Dec 2026	Investor Meeting	Mumbai	Physical	Group
9 Dec 2026	Investor Meeting	Mumbai	Physical	One-on-One
10 Dec 2026	DAM Capital Conference	Mumbai	Physical	Both

The schedule of the above-mentioned meeting may undergo changes due to exigencies on the part of Investor/ Company.

We request you to take this intimation on record.

Thanking you.

Yours faithfully,

For Glenmark Pharmaceuticals Limited

RASHMI KHANDELWAL

Digitally signed by RASHMI KHANDELWAL
Date: 2026.11.26 16:12:44 +05'30'

Rashmi Khandelwal
Company Secretary & Compliance Officer
ACS – 28839

Glenmark Pharmaceuticals Limited
Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099
T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com
Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com